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Recent interest has focused on antibodies that can discriminate between different receptor conforma-
tions. Here we have characterised the effect of a monoclonal antibody (mAb3), raised against a purified
thermo-stabilised turkey b1-adrenoceptor (b1AR-m23 StaR), on b1-ARs expressed in CHO-K1 or HEK 293
cells. Immunohistochemical and radioligand-binding studies demonstrated that mAb3 was able to bind
to ECL2 of the tb1-AR, but not its human homologue. Specific binding of mAb3 to tb1-AR was inhibited by
a peptide based on the turkey, but not the human, ECL2 sequence. Studies with [3H]-CGP 12177 demon-
strated that mAb3 prevented the binding of orthosteric ligands to a subset (circa 40%) of turkey
b1-receptors expressed in both CHO K1 and HEK 293 cells. MAb3 significantly reduced the maximum
specific binding capacity of [3H]-CGP-12177 without influencing its binding affinity. Substitution of
ECL2 of tb1-AR with its human equivalent, or mutation of residues D186S, P187D, Q188E prevented
the inhibition of [3H]-CGP 12177 binding by mAb3. MAb3 also elicited a negative allosteric effect on
agonist-stimulated cAMP responses. The identity of the subset of turkey b1-adrenoceptors influenced
by mAb3 remains to be established but mAb3 should become an important tool to investigate the nature
of b1-AR conformational states and oligomeric complexes.
 2017 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction target for approximately 30% of currently marketed (mostly smallG protein-coupled receptors (GPCRs) represent the largest class
of cell surface receptors in the human genome, and are the primarymolecule) drugs [1,2]. In recent years, however, there has been
renewed interest in the potential development of therapeutic anti-
bodies for this superfamily of cell surface receptors [3–5]. GPCRs
consist of seven transmembrane-spanning a-helices (TM1-7), an
extracellular N-terminus, an intracellular C-terminus, three extra-
cellular loops (ECL1-3) and three intracellular loops (ICL1-3). The
extracellular regions have the greatest diversity between different
GPCRs [6], even between closely related receptor subtypes such as
the b1- and b2-adrenoceptors, and are attractive immunogenic tar-
gets [7–9].
Epitope mapping and functional characterisation of GPCRs have
demonstrated that a major immunogenic epitope is located on the
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varies greatly between different GPCRs [7,8,13–16]. It has been
suggested to have roles in ligand recognition and selectivity for
the b-adrenoceptors [17–19], and has recently been implicated as
a site of allosteric modulation for the adenosine A1 receptor
[20,21]. The structure and position of the ECL2 is critical for
receptor conformation and activation [22,23]. Most interestingly,
pathogenic antibodies have been identified, that can activate the
b1-adrenoceptor by binding to ECL2, and lead to the development
of a form of cardiomyopathy [10,24]. Furthermore, different popu-
lations of antibodies directed at ECL2, isolated from patients, have
been reported to stabilise different b1-adrenoceptor conforma-
tions, affecting agonist-driven activation and subsequent receptor
desensitisation [25].
Recent advances in crystallisation techniques for GPCRs (such
as thermo-stabilised receptors: StaRs; [26,27]) have facilitated
the large-scale purification of stable GPCRs in a conformation
appropriate for both X-ray crystallography and their use as anti-
gens for monoclonal antibody generation. Previously, Hutchings
et al. [28] characterised a series of monoclonal antibodies (mAbs)
that were raised against the thermo-stabilised turkey
b1-adrenoceptor (b1AR-m23 StaR) [8]. These were found to bind
to the b1AR-m23 StaR [8] and were able to produce small cAMP
agonist responses in CHO cells transiently expressing the wild-
type turkey b1-adrenoceptor (tb1-AR) [28]. One mAb (mAb3) was
suggested to bind to an allosteric site on the tb1-AR, since there
were indications of non-competitive antagonism with the orthos-
teric antagonist dihydroalprenolol [28]. The aim of this study
was to investigate in more detail the pharmacology of mAb3 at
the human and turkey b1-adrenoceptors in cell lines stably
expressing each of these receptors.2. Materials and methods
2.1. Materials
[3H]-adenine, [3H]-CGP 12177, [14C]-cAMP, Microscint-20 and
Ultima Gold Scintillation fluid were from Perkin Elmer (Coventry,
West Midlands, UK). CGP 12177, CGP 20712A, cimaterol and ICI
118551 were from Tocris Bioscience (Bristol, UK). Decyl-b-D-
maltopyranoside was from Anatrace (Berkshire, UK). Purified
b1-m23-StaR [8] was provided by Heptares Therapeutics. The
following antibodies were used: goat-anti-mouse-Rhodamine
secondary antibody (Molecular Probes, Life Technologies, Paisley,
UK), horse radish peroxidase-conjugated secondary antibody (Cell
Signalling Technology, Leiden, The Netherlands). BODIPY-TMR-CGP
(CGP-12177-TMR) was purchased from Molecular Probes (Eugene,Table 1
Primers used to generate ECL2 tb6-m23 mutations. Complementary oligonucleotide primer
as described below. Lower case letters show the changed nucleotides. Mutations were desig
ligand binding (fmol/mg protein) obtained with each construct in CHO cells in the presen
Mutation Forward and reverse oligonucleotide primers (50 to 3
D184A CACTGGTGGCGGGcCGAGGACCCTCAG and CTGAGGG
D186S GTGGCGGGACGAGtcCCCTCAGGCGCTC and GAGCGCC
P187D GCGGGACGAGGACgaTCAGGCGCTCAAG and CTTGAG
Q188E GGACGAGGACCCTgAGGCGCTCAAGTG and CACTTGAG
L190R GAGGACCCTCAGGCGCgCAAGTGCTACCAGGACCCG an
K191R GAGGACCCTCAGGCGCTCAgGTGCTACCAGGACCCG an
Q194N GCGCTCAAGTGCTACaatGACCCGGGCTGCTGC and GC
G197K GTGCTACCAGGACCCGaaaTGCTGCGACTTTGTCAC and
D186S + P187D + Q188E GCGGGACGAGTCCgaTgAGGCGCTCAAG and CTTGAGCOR, USA). Fugene HD transfection reagent and furimazine were
from Promega (Southampton, UK). Purified turkey and human
ECL2 peptides were obtained from Cambridge Research Biochemi-
cals (Cambridge, UK). All other reagents were from Sigma-Aldrich
(Gillingham, UK).2.2. Constructs, cell lines and cell culture
To create the NL-tb6-m23 construct, NanoLuc (NL) was ligated
into pcDNA3.1 containing the 5-HT3A membrane localisation signal
sequence (sig) as previously described [29]. The tb6-m23 receptor
was then ligated to the C-terminus of NL from pcDNA3.1 with tb6-
m23 [30] using BamHI and XbaI restriction enzymes. Mutagenic
primers were then used to mutate the start codon of the tb6-
m23 receptor (Met into Leu) to create a fusion protein with a
Gly-Ser linker between the NL open reading frame and the tb6-
m23 open reading frame. Finally, to ensure there were no
mismatches in the plasmid potentially introduced from the muta-
genesis reaction, the NL-tb6-m23 fusion protein was ligated into a
fresh pcDNA3.1 plasmid using KpnI and XbaI restriction enzymes.
The ECL2 point mutations for tb6-m23 were generated using
QuickChange mutagenesis protocol (Stratagene, La Jolla, CA, USA)
see Table 1 for primer sequences. The triple ECL2 mutant of
D186S, P187D, Q188E was generated in two stages by sequential
point mutations. First, the single D186S mutation was made as
described above. Then, the triple mutant of D186S + P187D +
Q188E was made with primers in Table 1 using the single D186S
mutant sequence as the PCR template. All mutation sequences
were confirmed by DNA sequencing using the School of Life
Sciences Sequencing Facility at the University of Nottingham. Fol-
lowing successful mutagenesis, the mutant tb6-m23 receptor
cDNA was digested with BamHI/XhoI and subcloned into native
pcDNA3.1(+) containing a neomycin selection marker.
Chinese hamster ovary (CHO-K1) cells stably expressing either
the human b1-adrenoceptor, the C-terminally truncated turkey b-
adrenoceptor (tbtrunc; [31]), or an N-terminally truncated tbtrunc
with the m23 thermostabilising mutations (tb6-m23; [30,31])
were used in this study. In addition to the b-adrenoceptor, these
CHO-K1 cells also stably expressed a cyclic AMP response
element-secreted placental alkaline phosphatase (CRE-SPAP)
reporter gene. HEK 293 cells transiently expressing NL-tb6-m23
were also used in this study. Cells were cultured in Dulbecco’s
modified Eagle’s medium nutrient mix F12 (DMEM/F12, CHO cells)
or Dulbecco’s modified Eagle’s medium (DMEM, HEK cells) con-
taining 10% foetal calf serum and 2 mM L-glutamine in a 37 C
humidified 95% air/5% CO2 atmosphere. All CHO cell lines were
kindly provided by Prof. Jill Baker.s (50 to 30) used for site-directed mutagenesis containing the relevant mutations were
ned to convert turkey b1AR amino acids to their human equivalents. Levels of specific
ce of 0.5–2.5 nM [3H]-CGP 12177 are also shown.
0) Receptor expression
level (fmol/mg)
TCCTCGgCCCGCCACCAGTG 343 ± 40
TGAGGGgaCTCGTCCCGCCAC 264 ± 50
CGCCTGAtcGTCCTCGTCCCGC 237 ± 68
CGCCTcAGGGTCCTCGTCC 359 ± 92
d CGGGTCCTGGTAGCACTTGcGCGCCTGAGGGTCCTC 466 ± 10
d CGGGTCCTGGTAGCACcTGAGCGCCTGAGGGTCCTC 659 ± 67
AGCAGCCCGGGTCattGTAGCACTTGAGCGC 218 ± 50
GTGACAAAGTCGCAGCAtttCGGGTCCTGGTAGCAC 290 ± 63
GCCTcAtcGGACTCGTCCCGC 671 ± 31
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Purified b1AR-m23 StaR, [8] was immobilised through the cap-
ture of the C-terminal 6-His tag to Ni+-coated Nunc Immobilizer
96-well plates. Each well was coated with PBS containing 0.5 lg/
ml purified protein solubilised in 0.1% DM (n-Decyl-b-
maltopyranoside) and 100 lM alprenolol. Each well was blocked
with PBS containing 0.1% DM, 100 lM alprenolol and 3% milk pow-
der (blocking solution) for 1 h at room temperature. During this
stage, dilutions of mAb3 were incubated with 250 lg/ml or 500
lg/ml ECL2 peptide in blocking solution for 1 h (Human ECL2 pep-
tide: MHWWRAESDEARRCYNDPKCCDFVTN, Turkey ECL2 peptide:
MHWWRDEDPQALKCYQDPGCCDFVTN; Cambridge Research Bio-
chemicals, Cambridge, UK). Following this, each well was incu-
bated with the mAb3/ECL2 blocking solution for 1 h. Wells were
then washed with 3  200 ll of PBS with 0.05% Tween-20, 0.1%
DM and 100 lM alprenolol. A goat anti-mouse horseradish perox-
idase (HRP)-conjugated secondary antibody (1:1000) was added to
each well in 100 ll PBS with 0.05% tween-20, 0.1% DM and 100 lM
alprenolol. Bound antibody was detected using the 3,30,5,50-Tetra
methylbenzidine (TMB) liquid substrate system (Sigma-Aldrich,
Gillingham, UK). The absorbance was measured at 655 nm using
a POLARstar Omega plate reader (BMG Labtech, Germany).
2.4. Wide-field microscopy
Wide-field microscopy was performed using an ImageXpress
Micro XLS System microscope with a Plan Fluor ELWD 20 objec-
tive and a 4.66 megapixel CMOS camera for the acquisition of
images. CHO cells were grown to confluence in sterile black-
sided tissue culture-treated 96-well plates. For ECL2 competition
assays, cells were fixed with 3% paraformaldehyde in PBS for 15
min at room temperature. Cells were washed three times with
ice-cold PBS and blocked with 0.5% bovine serum albumin (BSA)
in PBS (blocking solution) for 30 min on a shaker (60 rpm) at 4
C. During this period, 66 nM mAb3 was incubated with the puri-
fied turkey or human ECL2 peptide in the blocking solution. The
blocking solution was removed from the cells and replaced with
the mAb3/ECL2 solution for 1 h at room temperature.
Cells were then washed three times with ice-cold PBS and then
incubated with the secondary antibody (goat anti-mouse-
Rhodamine Red IgG, 1:500 in 10% goat serum with PBS) for 1 h
in the dark at room temperature. This was then washed with three
ice-cold PBS washes before cells were stained with 2 lg/ml
Hoechst 33342 stain in PBS for 20 min. Three cold PBS washes
removed any excess stain and the plates were stored at 4 C in
the dark overnight before being imaged on the ImageXpress Micro
XLS Systemmicroscope (Molecular Devices, Wokingham, UK). Each
site was imaged twice, once with the ZPS DAPI filter (ex 405 nm) to
capture the Hoechst 33342 nuclear stain, and again with the ZPS
CY5/TRITC filter (ex 560 nm) to capture the Rhodamine from the
secondary antibody.
2.5. [3H]-CGP 12177 radioligand binding
All experiments were performed in Dulbecco’s modified
Eagle’s medium mix F12 containing 2 mM L-glutamine (serum-
free media). CHO cells were grown to confluence in sterile
white-sided, tissue culture-treated 96-well plates. For competi-
tion binding experiments, the media were aspirated from each
well and replaced with 50 ll serum-free media containing
[3H]-CGP 12177 within the range of 0.8–2.5 nM. Competing drugs
were added in 50 ll serum-free media to ensure thorough mixing
and the plates incubated at 37 C for 2 h. Non-specific binding
was determined with 10 lM propranolol. The serum-free media
were then removed and each well was washed twice with 200ll cold PBS. 100 ll Microscint-20 fluid was then added to each
well and the plates were sealed and left for several hours at room
temperature before being counted on a Topcount for 2 min per
well. For saturation experiments [3H]-CGP 12177 was used in
concentrations ranging from 0.01 to 40 nM. 10 lM propranolol
was used to define non-specific binding. When measuring
allosterism, mAb3 was allowed to bind to the tb6-m23 receptor
for 30 min at 37 C before the competing ligands or [3H]-CGP
12177 was added. The protein content of each well was deter-
mined as described previously [32].
2.6. NanoBRET ligand binding assay
Saturation- and competition-binding assays were performed
on transiently transfected HEK 293 NL-tb6-m23 cells. White 96-
well microplates were coated with 50 ml poly-D-lysine (10 mg/ml
in PBS) for 30 min and then washed with 100 ml PBS. Following
this, 5 ml transfection mix (Optimem with 100 ng NL-tb6-m23
plasmid DNA and 50 ml/ml Fugene HD transfection reagent) was
added to each well. 100 ml DMEM with cells in suspension
(20,000 cells/well) was then seeded onto these wells containing
the transfection mix to ensure complete mixing of the transfec-
tion mix and cells. After 24 h, the medium was removed from
each well and replaced with HEPES-buffered saline solution
(HBSS; 145 mM NaCL, 5 mM KCl, 1.7 mM CaCl2, 1 mM MgSO4,
10 mM HEPES, 2 mM sodium pyruvate, 1.5 mM NaHCO3, 10 mM
D-glucose, pH 7.45) with the relevant concentration of fluorescent
ligand and, if necessary, competing ligand or mAb3. Nonspecific
binding was determined with 10 mM propranolol. Cells were then
incubated for 1 h at 37 C in the dark. The NanoLuc substrate furi-
mazine (Promega, Southampton, UK) was then added to each well
at a final concentration of 10 mM and allowed to equilibrate for 5
min prior to reading. Luminescence signals were measured at two
different wavelengths using a PHERAstar FS plate reader (BMG
Labtech, UK) at room temperature. The filtered light from each
well was simultaneously measured using 460 nm (80-nm band-
pass) and >610 nm longpass filters. The resulting raw BRET ratio
was calculated by dividing the >610 nm emission by the 460
nm emission.
For saturation NanoBRET experiments with mAb3, HEK cells
transiently expressing NL-tb6-m23 were fixed with 3%
paraformaldehyde in PBS for 15 min at room temperature. Cells
were then washed three times with PBS before being incubated
with 100 ml PBS containing mAb3 in a concentration range of 1–
250 nM for 1 h at 37 C. The cells were then washed three times
with PBS and then incubated with the secondary antibody (goat
anti-mouse-Rhodamine Red IgG, 1:500 in 10% goat serum with
PBS) for 1 h in the dark at room temperature. Finally, furimazine
was added and the BRET was measured as described above.
2.7. [3H]-cAMP accumulation
CHO cells stably expressing the human or turkey b-
adrenoceptors were grown to confluence in sterile, clear, tissue
culture-treated 48-well plates. Cells were pre-labelled with
[3H]-adenine for 2 h with 2 lCi/ml [3H]-adenine at 37 C. Cells
were then washed by the addition and removal of 500 ll
serum-free media before the addition of 225 ll serum-free media.
Where used, 1 mM IBMX (3-isobutyl-1-methylxanine) was added
and incubated for 30 min before the addition of ligands. Ligands
were added in 25 ll serum-free media to the relevant wells and
the plates were incubated at 37 C for up to 5 h. 10 lM isopre-
naline was used to determine the maximal response in each plate
for each experiment. Where total [3H]-cAMP was measured, the
assay was terminated by the addition of 50 ll 12 M HCl to each
well and the plates were then frozen. Plates were subsequently
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sequential AG 50W-4X resin and alumina column chromatogra-
phy, using [14C]-cAMP to define column efficiency (as described
in [33]). Extracellular and intracellular [3H]-cAMP were measured
separately where stated. Here, the extracellular media were
removed after the given ligand incubation time and transferred
to a separate 48-well plate for the measurement of extracellular
[3H]-cAMP. The cells were washed by the addition and removal
of 2  500 ll serum-free media. 250 ll serum-free media was
then added to each well and the reaction terminated by the addi-
tion of 50 ll 12 M HCl to all wells (including those on the extra-
cellular [3H]-cAMP plate). Column separation of [3H]-cAMP from
other nucleotides was then performed as previously described
in [34].
2.8. CRE-mediated gene transcription (SPAP)
CHO cells stably expressing the CRE-SPAP reporter gene and
either human or turkey b-adrenoceptors were grown to conflu-
ence in sterile, clear, tissue culture-treated 96-well plates and
serum-starved 24 h before experimentation in serum-free media.
On the day of experimentation, media were aspirated from each
well and replaced with 90 ll fresh serum-free media. Ligands
were then added (in triplicate) in 10 ll serum-free media and
the plate was incubated at 37 C in a humidified 95% air/5% CO2
atmosphere for 5 h. 10 lM isoprenaline was used to determine
the maximal response in each plate for each experiment. Media
and compounds were then aspirated and replaced with 40 ll
serum-free media. Plates were incubated for a further hour at
37 C in the same atmosphere. The plates were then heated to
65 C for 25 min to destroy any endogenous alkaline phos-
phatases. After allowing them to cool to room temperature, 100
ll diethanolamine buffer (pH 9.85) containing p-nitrophenol
phosphate (PNPP) was added to each well and the plates incu-
bated at 37 C for 20 min in air. CRE-mediated SPAP reporter
activity was quantified by the colour change resulting from the
hydrolysis of PNPP. This was measured as the optical density at
405 nm using a Dynatech Laboratories MRX plate reader.
2.9. Data analysis
Data were analysed using Prism 6 software (GraphPad, San
Diego, USA).
Saturation radioligand-binding curves were fitted simultane-
ously for total ([3H]-CGP 12177 alone) and non-specific binding
(in the presence of 10 mM propranolol) using the following
equation:
Total binding ¼ BMAX  ½B½B þ KD þm ½B þ C
where Bmax is the maximal specific binding, [B] the concentration of
fluorescent ligand (nM), KD the equilibrium dissociation constant
(nM), M the slope of the non-specific binding component and C
the y axis intercept.
The affinity of CGP 20712A was calculated from radioligand
binding data with a one-site sigmoidal response curve given by
the following equation:
% uninhibited binding ¼ 100 ð100 ½A
nÞ
ð½An þ ICn50Þ
þ NS
where [A] is the concentration of CGP 20712A, NS is nonspecific
binding, n is the Hill coefficient, and IC50 is the concentration of
ligand required to inhibit 50% of the specific binding of [3H]-CGP
12177. The IC50 values were then used to calculate the Ki of CGP
20712A using the Cheng-Prussoff equation:Ki ¼ IC50
1þ ½LKD
where [L] is the concentration of [3H]-CGP 12177 in nM, and KD is
the dissociation constant of [3H]-CGP 12177 in nM.
The affinity of mAb3 was calculated from radioligand binding
data following the allosteric ternary complex model previously
described [35]:
IC50 ¼ KB ½A þ KAa½A þ KA
 
where IC50 is the concentration of allosteric modulator (B) required
for 50% inhibition of specific binding of a fixed concentration [A] of
radioligand, KA and KB are the dissociation constants for the radioli-
gand and allosteric modulator respectively, and a is the cooperativ-
ity factor between the allosteric modulator and radioligand.
Specific binding curves for CGP 12177 or mAb3 were fit to the
following equation:
Specific Binding ¼ BMAX  ½B½B þ KD
where Bmax is the maximal specific binding, [B] the concentration of
fluorescent ligand or mAb3 (nM) and KD the equilibrium dissocia-
tion constant (nM).
Agonist response curves were best described by a one-site sig-
moidal concentration response curve using the following equation:
Response ¼ Emax  ½A
EC50 þ ½A
where Emax is the maximum system response, [A] is the agonist con-
centration, and EC50 is the concentration of agonist required to pro-
duce 50% of the maximal response. The affinity of mAb3 was
estimated from [3H]-cAMP accumulation and CRE-SPAP reporter
gene assays using the model described in [36].
The relative activity (RA) was first calculated for isoprenaline in
the presence of each concentration of mAb3 using the following
equation:
RA ¼ Emax:EC
0
50
E0maxEC50
where RA is the relative activity of the agonist in the presence of the
allosteric modulator, E0max and EC
0
50 denote the Emax and EC50 values
of the agonist in the absence of the allosteric modulator, and Emax
and EC50 are the values measured of the agonist in the presence
of the allosteric modulator. This analysis was performed with the
constraint that the Hill slopes were equal to a value of 1.
To obtain an estimate for the affinity of mAb3, the RA obtained
at each concentration of mAb3 was plotted against the concentra-
tion of mAb3 (B). Nonlinear regression analysis of these data was
performed using the following equation in Prism 6:
logRA ¼ log 1þ c½B=KB
1þ ½B=KB
 
where KB is the dissociation constant of mAb3 (B), and c is the pro-
duct of the effects the mAb3 has on the intrinsic efficacy and affinity
of the agonist-receptor complex.
The time course of the [3H]-cAMP accumulation in response to
10 lM isoprenaline in tb6-m23 cells was fitted using the following
equation:
Y ¼ Ymaxð1 ekobs :tÞ
where
kobs = ([3H]-cAMP x kon) + koff.
kon and koff were shared across the data set to obtain a single
value for kobs. Y was [3H]-cAMP (dpm) at time t (min) and Ymax
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isoprenaline.
Inhibition of the steady-state levels of intracellular [3H]-cAMP
(produced by isoprenaline) following addition of mAb3 and CGP
20712A tb6-m23 cells were fitted using a one-phase exponential
decay equation:
Y ¼ ðY0  NSÞk:t þ NS
where Y0 represented the intracellular [3H]-cAMP at time 0, NS is
the intracellular [3H]-cAMP at infinite time, and k is the rate con-
stant of the decrease in intracellular [3H]-cAMP per minute.
Statistical significance was determined as p < 0.05 with paired
and unpaired t-tests, as well as one-way analysis of variance
(ANOVA). Goodness of statistical fits were analysed by a Partial F
test (Prism 6).3. Results
3.1. MAb3 binding to ECL2 of the purified turkey b1AR-m23 StaR
receptor
The crystal structure of the b1-adrenoceptor was first solved
using a thermo-stabilised turkey b1-AR (b1AR-m23 StaR) [8]. This
construct and the resulting protein produced were used to gener-
ate a panel of monoclonal antibodies using a combination of
cDNA immunization and protein boosting [28]. One of these anti-
bodies (mAb3) was demonstrated to bind to the b1AR-m23 StaR
expressed in HEK cells. Using purified proteins, the epitope of
mAb3 was suggested to be located on the second extracellular
loop (ECL2) of the turkey b1-AR [28]. Here, we investigated the
effect of a purified ECL2 peptide on the binding of mAb3 to the
b1AR-m23 StaR. Pre-incubation of mAb3 with purified turkey
b1-AR ECL2 (Tk ECL2) significantly reduced the specific binding
of mAb3 to the purified b1AR-m23 StaR in a concentration-
dependent manner (Fig. 1a, p < 0.05, one way ANOVA). In con-
trast, pre-incubation of mAb3 with purified human b1-AR ECL2
(Hu ECL2) did not significantly attenuate binding to b1AR-m23
StaR, but rather produced a significant increase in specific binding
at the highest concentrations of mAb3 used (33 nM and 6.6 nM;
Fig. 1b, p < 0.05, one way ANOVA).
3.2. Immunohistochemistry of mAb3 binding to CHO cells expressing
b1-ARs
With mAb3 showing strong binding to the purified b1AR-m23
StaR, we next investigated the binding capabilities of mAb3 in
CHO cells. Two CHO cell lines stably expressing the turkey b1-AR
were used in this study: a low expressing cell line (tbtrunc, recep-
tor expression level of 92 ± 14 fmol/mg protein, n = 8; determined
in this study with [3H]-CGP 12177 binding; [37]), and a high
expressing cell line (tb6-m23, receptor expression level 3128 ±
590 fmol/mg protein, n = 8; [30]). In addition, a CHO cell line stably
expressing the human b1-AR (hb1-AR) was used (receptor expres-
sion level 659 ± 77 fmol/mg protein, n = 6; [38]).
The specific binding of mAb3 to CHO cells expressing b1-ARs
was visualised using immunocytochemistry (Fig. 2). MAb3 was
able to specifically label the turkey b1-AR stably expressed on the
surface of intact CHO cells (Fig. 2a). CHO cells stably expressing
the human b1-AR (hb1-AR) did not display any binding of mAb3
(Fig. 2a). Quantitative analysis on these images calculated the aver-
age fluorescence intensity of cells as a measure of mAb3 binding.
The average cell intensity of the secondary antibody-only controls
was subtracted from the intensities of cells treated with mAb3 to
give a measure of the specific intensity of mAb3 binding (correctedcell intensity). CHO cells expressing the tbtrunc and tb6-m23
receptors had significantly higher average cell intensities than
the secondary antibody-only control (corrected average cell inten-
sities tb6-m23 55.0 ± 8.5 greyscale units; tbtrunc 15.3 ± 2.9 grey-
scale units; n = 4, Fig. 2b, p < 0.05, paired t-test). The relative
degree of mAb3 labelling was consistent with the relative receptor
expression levels calculated using radioligand binding. This analy-
sis also confirmed there was no specific binding of mAb3 to the
hb1-AR, since the average cell intensity did not significantly differ
from the secondary antibody-only control (corrected cell intensity
hb1-AR 2.3 ± 1.1 greyscale units; n = 4, Fig. 2b, p > 0.05, paired t-
test).
The specific binding of mAb3 to the turkey receptors was dis-
placed by addition of either 250 lg/ml or 500 lg/ml purified Tk
ECL2 peptide (Fig. 2c, d). Pre-incubation of mAb3 with Tk ECL2 at
both concentrations reduced specific binding to the tbtrunc recep-
tor to circa 50% that of mAb3 alone (250 lg/ml Tk ECL2, 49.0 ±
9.9%; 500 lg/ml Tk ECL2, 47.9 ± 5.3%, respectively; n = 4). This
effect was more pronounced in cells expressing the tb6-m23 recep-
tor. In these cells, the addition of Tk ECL2 resulted in only 31.2 ±
10.6% (250 lg/ml Tk ECL2) and 21.7 ± 6.6% (500 lg/ml Tk ECL2)
of the specific binding elicited by mAb3 alone (n = 4, Fig. 2d). Inter-
estingly, pre-incubation of mAb3 with Hu ECL2 peptide did not
result in a significant reduction of mAb3 binding to the tbtrunc
or tb6-m23 receptors (500 mg/ml 76.8 ± 32.6% tbtrunc; 88.0 ±
5.6% tb6-m23, Fig. 2e, p > 0.05 paired t-test).
3.3. Effect of mAb3 on the specific binding of [3H]-CGP 12177 to turkey
b1-adrenoceptors stably expressed in CHO cells
The radioligand [3H]-CGP 12177 was able to specifically bind to
the three b1-ARs used in this study to give KD values of 1.67 ± 0.41
nM (n = 7) for the tbtrunc, 0.93 ± 0.19 nM (n = 7) for the tb6-m23,
and 0.75 ± 0.13 (n = 13) for the hb1-AR. The b1-selective antagonist
CGP 20712A was able to compete with the specific binding of
[3H]-CGP 12177 in all three b1-ARs, yielding log Ki values of
7.23 ± 0.09 (n = 7) for the tbtrunc, 6.88 ± 0.13 (n = 7) for the
tb6-m23, and 8.70 ± 0.08 (n = 8) at the hb1-AR, respectively.
Increasing concentrations of mAb3 were also able to inhibit the
specific binding of [3H]-CGP 12177 to both the tbtrunc and
tb6-m23 receptors (Fig. 3a and b). However, the maximal inhibi-
tion of specific [3H]-CGP 12177 binding by mAb3 was lower than
that produced by the orthosteric antagonist CGP 20712A in the
same experiments (Fig. 3a and b, Table 2). Taken together with
the fact that the epitope of mAb3 was thought to be on ECL2
[28], these data suggested that mAb3 may be acting allosterically
with respect to the known small molecule orthosteric binding site
on the turkey b1-ARs. Statistical comparison was performed to
ascertain whether the allosteric ternary complex model (ATCM,
[35]) was the best model to describe these data. For both receptors,
globally analysing the data with the ATCM provided a better
description of the data than the standard three-parameter inhibi-
tion model (p < 0.001, tbtrunc; p < 0.05 tb6-m23, partial F test).
Application of the ATCM provided estimates for the affinity of
mAb3 at the tbtrunc and tb6-m23 receptors, as well as an estimate
for the cooperativity factor (a) between mAb3 and [3H]-CGP 12177
(Table 2). From these analyses, mAb3 had similar affinities at the
tbtrunc (log KB 7.56 ± 0.08) and at the tb6-m23 (log KB 7.70 ±
0.09). The estimated a values at both tbtrunc and tb6-m23 sug-
gested a high degree of negative cooperativity between mAb3
and [3H]-CGP 12177 at these receptors. There was no evidence of
mAb3 binding to the hb1-AR (Fig. 3c), which was consistent with
the data obtained with the purified Hu ECL2 peptide.
To investigate further the role that the ECL2 plays in the binding
of mAb3 to the full length receptor, a mutant tb6-m23 receptor
construct was made whereby the Tk ECL2 was mutated to the Hu
Fig. 1. ELISA showing the effect of a (a) turkey or (b) human ECL2 peptide sequence (250 lg/ml or 500 lg/ml) on the binding of different concentrations of mAb3 to purified
b1AR-m23 StaR. Included are controls for the secondary antibody alone, and the secondary antibody in combination with the relevant peptide. Bars are mean ± s.e.m. of
triplicate determinations and these single experiments are representative of four separate experiments. *p < 0.05, **p < 0.01, ***p < 0.001, comparing binding of mAb3 at b1AR-
m23 StaR to the other conditions, one-way ANOVA with Dunnett’s post hoc test.
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siently expressed in CHO cells. Specific binding of [3H]-CGP
12177 was observed at this receptor (KD 7.85 ± 0.88 nM, Bmax
2857 ± 262 fmol/mg protein; n = 4), demonstrating that the result-
ing receptor protein was expressed on the plasma membrane.
Increasing concentrations of propranolol were able to inhibit the
specific binding of [3H]-CGP 12177 (log Ki propranolol 6.73 ±
0.08; n = 5). However, as with the hb1-AR, mAb3 could not bind
to the tb6-m23-hECL2 receptor (Fig. 3d), further suggesting that
the epitope of mAb3 existed entirely within the turkey ECL2.
The turkey ECL2 is 26 amino acids in length and shares 70%
identity with the human ECL2. The eight residues that differ
between the two species have been highlighted on the recently
solved b1AR-m23 StaR crystal structure [39] (Fig. 4a-c). The major-
ity of these residues exist on the extracellular surface of the loop
(Fig. 4a), with side chains facing away from the ligand-binding
pocket, projecting into the extracellular space (Fig. 4c). In order
to elucidate which residues were necessary for the binding of
mAb3, a series of single point mutations were made, changingthe turkey residue to the equivalent human residue. The eight
mutations were as follows: D184A, D186S, P187D, Q188E, L190R,
K191R, Q194N, and G197K (Fig. 4d). Similar levels of specific bind-
ing of [3H]-CGP 12177 were obtained with all mutant constructs
(Table 1). Single point mutations did not significantly affect the
binding of mAb3 (Fig. 4e), demonstrating that the epitope of
mAb3 was not susceptible to the loss of a single residue. Given this
fact, we then looked for clusters of amino acids that may be
responsible for the mAb3 epitope. Residues D186, P187, Q188 were
all located on the N-terminus of the a-helix in ECL2, and offered a
potential target. Therefore, a chimeric tb6-m23 receptor containing
the triple mutation D186S, P187D and Q188E was made (Table 1).
Interestingly, 1 mM mAb3 did not displace the specific binding of
[3H]-CGP 12177 at this receptor (Fig. 4e). These data suggest that
this cluster of three amino acids is necessary for mAb3 binding.
The potential allosteric nature of the interaction of mAb3 with
the tb1-AR was further investigated using ligand binding assays.
CHO tb6-m23 cells were incubated with increasing concentrations
of [3H]-CGP 12177 in the absence and presence of 200 nM mAb3
Fig. 2. (a) Wide-field microscopy of mAb3 binding to fixed CHO cells expressing tbtrunc, tb6-m23 or hb1-AR. Cells were treated with 10 lg/ml (66 nM) mAb3 for one hour at
room temperature. Images show the localisation of mAb3 staining (upper panels) and Hoechst 33342 nuclear stain (lower panels). Scale bar is 20 lm and applies to all panels.
Images were obtained from a single experiment and this is representative of four separate experiments. (b) Average cell intensity of images shown in (a) in greyscale units.
Specific binding of mAb3 at (c) tbtrunc, (d-e) tb6-m23 in the absence and presence of 25 lg or 50 lg turkey ECL2 (Tk ECL2, c-d) or 25 lg or 50 lg human ECL2 (Hu ECL2, e).
(c–e) values are specific mAb3 binding, as the intensity of 2 only has been subtracted. (b–e) Data points are mean ± s.e.m. from triplicate determinations in a single
experiment. These single experiments are representative of four separate experiments. *p < 0.01, **p < 0.001, comparing (b) average cell intensity at tbtrunc and tb6-m23 to
the 2 only control or (c–d) the average cell intensity of mAb3 binding in the presence of TkECL2 to that of Mab3 IgG alone, one-way ANOVA.
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± 0.18 nM (n = 3), and the affinity of [3H]-CGP 12177 in the pres-
ence of 200 nM mAb3 was not significantly changed (4.13 ± 0.54
nM; n = 3, p > 0.05, paired t-test). However, the addition of 200
nM mAb3 resulted in a reduced Bmax of [3H]-CGP 12177(58.4 ± 13.9% total specific binding; p < 0.05 compared to specific
binding in the absence of mAb3, paired t-test).
Competition [3H]-CGP 12177 binding assays with the orthos-
teric ligands isoprenaline, propranolol and CGP 20712A were also
performed in the absence and presence of 200 nM mAb3
Fig. 3. [3H]-CGP 12177 radioligand binding in whole CHO cells expressing (a) tbtrunc, (b) tb6-m23 (c) hb1-AR or (d) tb6-m23-hECL2 in the presence of increasing
concentrations of (a-c) mAb3, CGP 20712A, or (d) mAb3, propranolol. The concentration of [3H]-CGP 12177 used was (a) 0.56 nM, (b) 0.67 nM (c) 0.56 nM and (d) 0.76 nM.
Bars indicate total [3H]-CGP 12177 binding and [3H]-CGP 12177 binding in the presence of 10 lM propranolol. Data are mean ± s.e.m. of (a-c) hexuplicate or (d) triplicate
determinations in a single experiment. These single experiments are representative of (a) seven, (b) seven (c) eight or (d) five separate experiments.
Table 2
Log IC50, log KB, a values and % maximal inhibition of [3H]-CGP 12177 binding obtained from [3H]-CGP 12177 whole cell radioligand binding studies in CHO cells stably expressing
either the tbtrunc, tb6-m23, or hb1-adrenoceptors. Maximal inhibition of specific [3H]-CGP 12177 binding was determined in the presence of 10 lM propranolol. Data are mean ±
s.e.m. from n separate experiments. NI – No inhibition. The ATCM (allosteric ternary complex model; [35]) was performed to obtain the log KB of mAb3 using a global fit. *p < 0.05
comparing maximal inhibition to 100% representing complete inhibition of specific binding with 10 lM propranolol, unpaired t-test. yp < 0.05, p < 0.001, comparing ATCM fit to
three-parameter inhibition curve, F-test.
CHO Cell Line Log IC50 mAb3 % Max Inhibition of [3H]-CGP 12177 binding ATCM fit Preferred fit
10 lM CGP 20712A 1 lM mAb3 n Log KB mAb3 mAb3 a value Partial F-test
tbtrunc 7.48 ± 0.12 84.3 ± 3.9* 63.4 ± 7.1* 7 7.56 ± 0.08 0.06 ± 0.03 ATCM
tb6-m23 7.32 ± 0.12 94.7 ± 0.5* 77.5 ± 4.5* 7 7.70 ± 0.09 0.05 ± 0.02 ATCMy
hb1-AR NI 99.6 ± 0.3 NI 8 NI NI –
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showed good agreement with previously published affinities [30]
at the tb6-m23 receptor (isoprenaline log Ki 5.03 ± 0.17, propra-
nolol log Ki 7.62 ± 0.15, CGP 20712A log Ki 6.19 ± 0.14; n = 5
for each ligand in this study). The addition of 200 nM mAb3
resulted in a reduction in the specific binding of [3H]-CGP 12177
(54.4 ± 1.1% of the specific binding in the absence of mAb3; n =5). The addition of mAb3 did not significantly change the affinity
of the antagonists propranolol or CGP 20712A (log Ki values
7.96 ± 0.11, 6.64 ± 0.15, respectively; n = 5, p > 0.05 unpaired
t-test). However, mAb3 appeared to produce a small but significant
increase in the affinity of isoprenaline (log Ki with 200 nM mAb3
5.63 ± 0.10; n = 5, p < 0.05 compared to isoprenaline Ki in absence
of mAb3, unpaired t-test).
Fig. 4. Ribbon representation of the b1AR-m23 StaR structure bound to isoprenaline (PDB ID: 2Y03; [39]) generated with Cn3D (National Centre for Biotechnology
Information). (a) Side view and (b) top view of receptor highlighting the ECL2 residues (coloured as in (d)) which differ between the turkey and human b1-AR sequences. The
structure of isoprenaline is also shown. (c) Top view of ECL2 with side chains of residues (coloured) that differ from the human b1-AR sequence. (d) Amino acid sequence of
ECL2 for turkey and human b1-AR, with residue differences highlighted. (e) Specific binding of 0.5–2.5 nM [3H]-CGP 12177 in the presence of 1 mM mAb3 in CHO cells
transiently expressing wildtype tb6-m23 or ECL2 mutant constructs (where residues have been changed from the turkey amino acid to their human equivalent). Data are
represented as a % of the specific binding of [3H]-CGP 12177 in the presence of mAb3. Non-specific binding was defined with 10 mM propranolol. Data are mean ± s.e.m. The
number of separate experiments performed for each mutant are given in parentheses above each bar. Triplicate determinations were performed in each individual
experiment. *p < 0.05 comparing the inhibition specific binding by 1 mM mAb3 in that ECL2 mutant to the wild-type receptor, one-way ANOVA. (For interpretation of the
references to colour in this figure legend, the reader is referred to the web version of this article.)
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shared IC50 or BMAX values also confirmed a significant decrease
in BMAX (p < 0.0001) and a small increase in affinity for isoprenaline
in the presence of mAb3 (log IC50 values of 4.3 and 4.9 in the
absence and presence of 200 nM mAb3; p < 0.0001; Partial F-test,
Prism 6). For the propranolol data, a similar analysis of Fig. 5b onlyproduced a significant reduction in BMAX in the presence of 200 nM
mAb3 (p < 0.0001; Partial F-test). However, analysis of the
CGP20712A curves indicated a small decrease in IC50 (log IC50 of
5.9 in the presence of 200 nM mAb3 compared to 5.5 in its
absence; p < 0.05) and a marked reduction in BMAX (p < 0.001; Par-
tial F-test).
Fig. 5. (a) [3H]-CGP 12177 radioligand binding in whole CHO tb6-m23 cells in the
absence and presence 200 nM mAb3. Non-specific binding was defined in the
presence of 10 mM propranolol. Data points are mean ± s.e.m from triplicate
determinations in a single experiment and this single experiment is representative
of three separate experiments. (b) Inhibition of 0.4–1.8 nM [3H]-CGP 12177 binding
to CHO tb6-m23 cells by ligands in the absence and presence of 200 nMmAb3. Data
points are expressed as a % of the specific binding of [3H]-CGP 12177 obtained in the
absence of an inhibitor in each experiment. Non-specific binding was defined in the
presence of 10 mM propranolol. Data points represent the mean ± s.e.m. from five
separate experiments where each experiment was performed in duplicate.
Fig. 6. (a) Schematic showing CGP 12177-TMR (CGP-TMR) binding to (NanoLuc
tagged NL-tb6-m23 using NanoBRET. (b) Saturation binding of increasing concen-
trations of CGP-12177-TMR (CGP-TMR) in the absence and presence of 20 nM or
200 nM mAb3. Non-specific binding was defined in the presence of 10 mM
propranolol. Data points represent mean ± s.e.m. from four separate experiments
where each experiment was performed in duplicate.
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Proximity-based assays have provided a platform to monitor
GPCR function and dimerization with great success [40,41]. Recent
advances in the brightness and stability of luciferases (e.g. Nano-
Luc, [42]) have facilitated the use of bioluminescence resonance
energy transfer (BRET) to monitor fluorescent ligand binding at
GPCRs [29,43], and at a receptor tyrosine kinase [44]. Here we have
utilised an N-terminal NanoLuc-tagged tb6-m23 receptor (NL-tb6-
m23) expressed in HEK 293 cells to measure the binding of the
fluorescent ligand CGP-12177-TMR [29,43,45] to the turkey b1-
adrenoceptor expressed in HEK 293 cells (Fig. 6a). CGP-12177-
TMR showed clear specific binding to the NL-tb6-m23 receptor
(Fig. 6b). These data provided an estimate for the KD value of
CGP-12177-TMR of 17.8 ± 4.0 nM (n = 4, Fig. 6b). Incubation of
CGP-12177-TMR with 20 nMmAb3 resulted in no significant effect
on the affinity of CGP-12177-TMR (KD 31.1 ± 11.2; n = 4, pairedt-test) or on the specific BRET ratio (87.7 ± 10.9% Bmax; n = 4, paired
t-test, Fig. 6b) The addition of mAb3 at circa ten times KD (200 nM)
resulted in a significant decrease in the specific BRET ratio (39.9 ±
9.3% Bmax; n = 4, p < 0.05 paired t-test, Fig. 6b) without any signif-
icant effect on the affinity of CGP-12177-TMR (KD with 200 nM
mAb3 39.3 ± 11.4 nM; n = 4, p > 0.05 paired t-test).
NanoBRET was also used to quantify the direct binding of mAb3
to the NL-tb6-m23 receptor. In these experiments, mAb3 was
allowed to bind the turkey ECL2, and was then treated with a
fluorescently-conjugated secondary antibody. Upon luciferase sub-
strate addition, the BRET between the luciferase and a rhodamine-
tagged secondary antibody (bound to mAb3) was then quantified
(Fig. 7a). The concentration of the secondary rhodamine-tagged
antibody was kept constant across all conditions. Increasing con-
centrations of mAb3 resulted in an increase in the BRET ratio with
a clear saturable component (Fig. 7b, c). From these data, the affin-
ity of mAb3 for the NL-tb6-m23 receptor in HEK cells was calcu-
lated to be 19.5 ± 4.7 nM (n = 4, Fig. 7c).3.5. Effect of mAb3 on b1-adrenoceptor-mediated Gs signalling in
stable cell lines
The tb1-AR couples to Gs proteins, and therefore activation of
the tb1-AR results in an increase in intracellular cAMP and activa-
tion of the protein kinase A signalling pathway [31,37]. Here, we
examined the potential for mAb3 to stimulate CRE-SPAP gene
expression or [3H]-cAMP accumulation in the presence of 1 mM
of the phosphodiesterase inhibitor IBMX via the tbtrunc and tb6-
m23 receptors when stably expressed in CHO cells.
The full agonist isoprenaline (10 lM) was able to stimulate an
increase of [3H]-cAMP over basal levels after a five hour incubation
(tbtrunc 6.25 ± 0.35-fold, n = 5; tb6-m23 27.50 ± 4.28-fold, n = 21;
Fig. 8a, c). Similarly, 10 lM isoprenaline resulted in an increase
Fig. 7. (a) Schematic showing MAb3 binding to the NL-tb6-m23 detected using a fluorescently-labelled secondary goat anti-mouse antibody that recognises the murine
mAb3. BRET occurs between the Nanoluc and the rhodamine fluorophore of the secondary antibody. (b, c) NanoBRET signal obtained from fixed HEK 293 cells (which had
been previously transfected with the NL-tb6-m23 receptor) following incubation with increasing concentrations of mAb3 and subsequent exposure to a rhodamine-labelled
goat anti-mouse secondary antibody. Non-specific binding was determined in the presence of the secondary antibody alone. Data points are mean ± s.e.m. of four separate
experiments where each experiment was performed in duplicate. Data are expressed (b) as the mean specific BRET ratio (after subtraction of the secondary antibody control
values) obtained in the four experiments at each concentration of mAb3 or (c) as a % of the binding obtained with 250 nM mAb3 in each individual experiment.
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± 0.05 (n = 20) fold over basal for tbtrunc and tb6-m23 receptors,
respectively (Fig. 8b, d). MAb3 was unable to stimulate a change
in [3H]-cAMP or CRE-mediated SPAP production at either the
tbtrunc or tb6-m23 receptors (Fig. 8, p > 0.05 comparing response
of mAb3 to basal [3H]-cAMP accumulation or SPAP production).
3.6. The effect of mAb3 on agonist-induced signalling in stable cell lines
expressing the at the turkey b1-adrenoceptor
To investigate whether mAb3 could antagonise isoprenaline–
stimulated responses, CHO cells stably expressing the tbtrunc or
tb6-m23 receptors were stimulated with a range of concentrations
of isoprenaline in the absence and presence of mAb3. Thirty min-
ute pre-incubation with mAb3 was able to antagonise
isoprenaline-mediated SPAP production at both the tbtrunc
(Fig. 9a) and tb6-m23 (Fig. 9b) receptors in a concentration-
dependent manner, resulting in a series of rightward shifts in the
isoprenaline concentration-response curves and a reduction in
Emax (Table 3). Schild analysis gave Hill slopes of 0.91 ± 0.14 at
the tbtrunc, and 0.68 ± 0.05 at the tb6-m23 receptors. The value
obtained at the tb6-m23 receptor significantly differed from unity(p < 0.05, unpaired t-test comparing to unity), which suggested a
non-competitive interaction between mAb3 and isoprenaline. It
is clear from the radioligand binding studies (above) that mAb3
is acting allosterically on a sub-population/conformation of the
b1AR. It is therefore likely that the antagonism of functional
responses to isoprenaline by mAb3 is due to the gradual loss of this
population of b1AR. For these reasons, functional data were also
analysed using equations for an allosteric modulator derived from
the functional model previously described [36,46]. First, the rela-
tive activities of the isoprenaline concentration response curves
in the presence and absence of mAb3 were calculated. Regression
analysis of these relative activity values was then used to obtain
an estimate for the affinity of mAb3. The resulting affinity of
mAb3 was similar at the two turkey receptors (tbtrunc log KB
7.39 ± 0.11, n = 5; tb6-m23 log KB 7.50 ± 0.09, n = 5), which
share good agreement with the affinity of mAb3 at these receptors
measured with radioligand binding.
The same effect was observed when measuring [3H]-cAMP
accumulation in the high expressing tb6-m23 cell line in the pres-
ence of 1 mM IBMX. Increasing concentrations of mAb3 resulted in
rightward shifts and reduction in Emax in the concentration-
response curves of isoprenaline after a five hour incubation
Fig. 8. [3H]-cAMP accumulation and CRE-mediated SPAP production in CHO cells expressing the (a-b) tbtrunc or (c-d) tb6-m23 receptor. (a,c) [3H]-cAMP accumulation in
response to mAb3. (b,d) CRE-mediated SPAP production in response to mAb3 and cimaterol. Bars indicate basal (a,c) [3H]-cAMP accumulation, (b,d) basal CRE-mediated SPAP
production, and that in response to 10 lM isoprenaline. Data are mean ± s.e.m. of triplicate determinations in a single experiment. These single experiments are
representative of (a,c,d) five, or (b) eleven separate experiments.
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mAb3 did not have any effect on the partial agonist response of
CGP 12177 (Fig. 10b; Table 4).
3.7. MAb3 induces the dissociation of isoprenaline from the receptor
To investigate whether mAb3 binding to ECL2 was truly acting
as (a) a negative allosteric regulator or (b) sterically interfering
with the association or dissociation of ligands from the orthosteric
binding site of the thermo-stabilised b1AR-m23 StaR, we investi-
gated the effect of mAb3 on the kinetics of the intracellular cAMP
response to isoprenaline. Isoprenaline (1lM) caused an increase in
the intracellular [3H]-cAMP concentration until equilibrium was
reached after circa thirty minutes (Fig. 11a). The addition of 10
lM CGP 20712A at equilibrium resulted in a sharp decrease in
the concentration of intracellular [3H]-cAMP that could be fitted
to a one-phase exponential decay curve (Fig. 11a). This was quan-
tified by calculating an apparent rate constant for this effect (0.118
± 0.012 min1; n = 5) that reflects the rate for the dissociation of
isoprenaline from the ligand binding pocket and the subsequentbreakdown of [3H]-cAMP. In contrast, the addition of serum-free
media without any additional ligand did not result in any signifi-
cant change in the intracellular levels of [3H]-cAMP suggesting that
there was no significant dissociation of isoprenaline from the
receptor over this time period (p > 0.05, unpaired t-test comparing
1 lM isoprenaline with serum free media to that of 100% obtained
in the presence of 1 lM isoprenaline alone; n = 5; data not shown).
1 lMmAb3 was able to cause a similar decrease in intracellular
[3H]-cAMP with a rate constant of 0.046 ± 0.001 min1 (n = 5;
Fig. 11b). This was significantly different from the rate constant
obtained with CGP 20712A (p < 0.05, unpaired t-test). In combina-
tion, 1 lM mAb3 and 10 lM CGP 20712A resulted in a high rate
constant (0.108 ± 0.011 min1, n = 5) that was not significantly dif-
ferent from that obtained with 10 lM CGP 20712A alone (p > 0.05,
unpaired t-test; Fig. 11b). Cells were also treated with 1 lM mAb3
for the first sixteen minutes prior to the addition of 10 lM CGP
20712A. As can be seen in Fig. 11b, the initial reduction in intracel-
lular [3H]-cAMP with mAb3 followed a similar time course to that
previously seen with 1 lM mAb3. However, upon subsequent
addition of 10 lM CGP 20712A in combination with 1 lM mAb3
Fig. 9. CRE-mediated SPAP production in CHO cells expressing the (a) tbtrunc or (b)
tb6-m23 receptor in response to isoprenaline in the absence and presence of 10 nM,
100 nM and 1 lM mAb3. Bars represent the basal SPAP production, and that in
response to 10 nM, 100 nM and 1 lM mAb3. Data points are mean ± s.e.m. of
triplicate determinations in a single experiment and are representative of five
separate experiments.
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accelerated to match that of 10 lM CGP 20712A alone.4. Discussion
MAb3 was originally generated against a thermo-stabilised
b1AR-m23 StaR [28]. Here, we have demonstrated specific bindingTable 3
Log EC50 values, concentration ratios, relative activity, and Emax as a percentage of 10 lM
cells. Cells were treated with isoprenaline in combination with differing concentrations of m
presence of mAb3 from that in its absence. Relative activity represents the effect mAb3 h
Methods. Data for each condition are mean ± s.e.m. from five individual experiments perfor
unpaired t-test.
Ligand tbtrunc
Log EC50 Concentration Ratio Emax % max Relative
Isoprenaline 8.32 ± 0.15 – 100 1
Iso + 10 nM mAb3 8.30 ± 0.24 1.31 ± 0.28 109 ± 8 0.87 ± 0.1
Iso + 100 nM mAb3 7.88 ± 0.16 2.75 ± 0.32 96 ± 8 0.30 ± 0.0
Iso + 1 lM mAb3 7.04 ± 0.15 21.99 ± 6.2 82 ± 10 0.05 ± 0.0of mAb3 to the purified turkey b1AR-m23 StaR protein. Further-
more, binding of mAb3 to b1AR-m23 StaR protein was significantly
inhibited by a turkey b1-AR ECL2 peptide confirming that the likely
epitope for the antibody was in ECL2 as originally proposed by
Hutchings et al. [28]. However, it was notable that the human
ECL2 peptide did not attenuate mAb3 binding.
Two CHO cell lines expressing different mutant turkey b1-
adrenoceptors were used to investigate the pharmacology of
mAb3 in intact cellular systems. These were cells stably expressing
either a C-terminal truncated wild-type turkey b-adrenoceptor
(tbtrunc; [31]) or a variant containing m23 thermo-stabilising
mutations (tb6-m23; [30]). The binding of mAb3 resulted in a
concentration-dependent attenuation of the specific binding of
[3H]-CGP 12177 to both tb1-ARs. Applying an allosteric ternary
complex model to these data enabled an estimate of the affinity
of mAb3 for both the low expressing tbtrunc and high expressing
tb6-m23 receptors to be determined. This did not significantly dif-
fer between the two tb1-AR variants (the dissociation constant KB
was circa 20–25 nM in both cell lines). The primary sequences of
the ECL2 in these two receptors are identical, implying that m23
mutations present in the tb6-m23 receptor did not significantly
change the conformation of the ECL2. The cooperativity factor
between mAb3 and [3H]-CGP 12177 was also similar for the two
tb1-ARs and indicated a high degree of negative cooperativity in
both cases (Table 2). These data are consistent with a previous sug-
gestion that mAb3 may behave as an allosteric modulator of
[3H]-dihydroalprenolol binding [28].
The specific binding of mAb3 to CHO cells expressing b1-ARs
was also visualised using immunocytochemistry. These data con-
firmed that mAb3 could selectively detect only tb1-adrenoceptors
(both tbtrunc and tb6-m23 variants) in intact cells and was not
able to bind to the human b1-adrenoceptor. It was also able to
detect tbtrunc at very low expression levels (92 ± 14 fmol/mg pro-
tein) and mAb3 binding could be inhibited by a turkey ECL2 pep-
tide, but not by the equivalent human ECL2 peptide.
The human ECL2 shares 70% homology with the Tk ECL2
(Fig. 4d). The human b1-AR ECL2 primary sequence differs from
the Tk ECL2 by only eight residues. Single point mutations of these
turkey residues to their human equivalent did not affect the bind-
ing of mAb3 in cells transiently transfected with the relevant vari-
ant of the t b6-m23 receptor. All showed a 38–60% reduction on
the specific binding of 0.5–2.5 nM [3H]-CGP 12177 in the presence
of 1 lM mAb3. However, a triple mutant (D186S, P187D, Q188E)
abolished the negative effect of mAb3 on the binding of [3H]-
CGP12177 to the t b6-m23 receptor. Interestingly, substitution of
the full human ECL2 sequence in place of the turkey ECL2 in tb6-
m23 showed the same effect as the triple mutant, suggesting that
residues D186, P187 and Q188 are necessary for mAb3 binding.
Mapping these residues to the b1AR-m23 StaR crystal structure
(PDB ID: 2Y03; [39]) indicate that the majority of these residues
are located on the extracellular facing surface of the ECL2
(Fig. 4). It is worth pointing, however, that mutation the threeisoprenaline-stimulated CRE-SPAP production in CHO tbtrunc or tb6-m23 CRE-SPAP
Ab3 for five hours. Concentration ratios were determined by dividing the EC50 in the
as on the potency and efficacy of isoprenaline, and was derived as described under
med in triplicate. *p < 0.05 comparing Emax to 100%, or relative activity to a value of 1,
tb6-m23
activity Log EC50 Concentration Ratio Emax % max Relative activity
7.24 ± 0.13 – 100 1
1 7.11 ± 0.13 1.50 ± 0.27 96 ± 5 0.77 ± 0.12*
5* 6.69 ± 0.14 3.84 ± 0.34 90 ± 6 0.26 ± 0.03*
1* 5.92 ± 0.14 24.39 ± 4.1 70 ± 9* 0.04 ± 0.01*
Fig. 10. [3H]-cAMP accumulation in CHO tb6-m23 cells in response to (a)
isoprenaline or (b) CGP 12177 in the absence and presence of 10 nM, 100 nM and
1 lM mAb3 for five hours. Bars represent the basal [3H]-cAMP accumulation, and
that in response to 10 nM, 100 nM and 1 lMmAb3. Data points are mean ± s.e.m. of
triplicate determinations in a single experiment and are representative of five
separate experiments.
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also alter the three dimensional packing of ECL2, and that this
could mask the true mAb3 binding epitope. However, either way,
these mutations do explain the species selectivity of mAb3.
The potential allosteric nature of the interaction of mAb3 with
the turkey b1-AR was further investigated using ligand-bindingTable 4
Log EC50 values, concentration ratios, relative activity and Emax as a percentage of 10 lM
response to five hour stimulation with isoprenaline or CGP 12177 in combination with dif
EC50 (in M) in the presence of mAb3 from that in its absence. Data for each condition a
comparing Emax to 100%, or relative activity to a value of 1, unpaired t-test.
Ligand Isoprenaline
Log EC50 Concentration Ratio Emax % iso max
Ligand 6.61 ± 0.13 – 100
Ligand + 10 nM mAb3 6.51 ± 0.12 1.53 ± 0.22 106 ± 4
Ligand + 100 nM mAb3 5.98 ± 0.10 5.24 ± 0.60 86 ± 6*
Ligand + 1 lM mAb3 5.45 ± 0.12 17.68 ± 2.35 57 ± 4*assays. CHO tb6-m23 cells were incubated with increasing concen-
trations of [3H]-CGP 12177 in the absence and presence of mAb3.
In these experiments the KD of [3H]-CGP 12177 was not signifi-
cantly changed by the presence of 200 nM mAb3. However, the
addition of 200 nM mAb3 did produce a significant 42% reduction
in the maximal specific binding capacity of [3H]-CGP 12177. This
suggests that mAb3 had effectively ‘removed’ a significant propor-
tion of the b1-adrenoceptor population that is available to bind
[3H]-CGP 12177. Competition binding assays using 0.4–1.8 nM
[3H]-CGP 12177 and a range of orthosteric ligands (in the presence
or absence of mAb3) were consistent with this conclusion. Thus,
the affinities of CGP 12177 and CGP 20712A obtained in the pres-
ence of 200 nM mAb3 were similar to those obtained in the
absence of mAb3, with a small increase in the affinity of isopre-
naline. There was, however, a significant decrease (46%) in the
specific binding capacity of [3H]-CGP 12177 in the absence of the
orthosteric ligands.
To gain some insight into the percentage of receptors occupied
by mAb3 at the concentrations used in the present study, we
have used a NanoBRET binding assay [43]. Using a similar
approach to that we have previously reported in HEK 293 cells
to study human b1- and b2-adrenoceptors [29,43], we demon-
strated that a fluorescent analogue of CGP 12177 (CGP-12177-
TMR) could be used to monitor the effect of mAb3 on the KD
and maximal specific binding capacity of CGP-12177-TMR to an
N-terminal NanoLuc-tagged variant of the tb6-m23 receptor.
These data showed a similar 40% reduction in maximal specific
binding in the presence of 200 nM mAb3 without any significant
effect on the affinity of CGP-12177-TMR. NanoBRET was also used
to monitor directly the affinity of mAb3 for NL-tb6-m23
expressed in HEK 293 cells using NanoBRET between a
rhodamine-labelled secondary antibody to mAb3 and the extra-
cellular Nanoluc of NL-tb6-m23. The affinity of mAb3 measured
at the NL-tb6-m23 receptor (KD 17.8 nM) was very similar to that
(19.5 nM) estimated from radioligand binding studies at the tb6-
m23. The large size of the mAb3-secondary antibody complex
does, however, mean that we can only conclude that the rho-
damine on the secondary antibody was in close proximity (<10
nm) to the NanoLuc of a neighbouring b1-adrenoceptor rather
than definitively conclude that it is to the b1-adrenoceptor to
which mAb3 was bound. Notwithstanding these uncertainties,
we can conclude that the occupancy achieved at the turkey
b1-adrenoceptor with 200 nM and 1 mM mAb3 was very high
(92 and 98% respectively).
Taken together, these data suggest that mAb3 binds to ECL2 of
the turkey b1-adrenoceptor and acts allosterically to prevent the
binding of orthosteric ligands to a subset (circa 40%) of b1-
receptors present in the cells. The interaction of mAb3 with ECL2
and its consequent allosteric effects are consistent with the impor-
tant role that ECL2 appears to have in ligand recognition [17–19]
and as a site of allosteric modulation for other GPCRs [20,21]. Fur-
thermore, the structure and position of the ECL2 is known to be
critical for receptor activation [22,23].isoprenaline-stimulated [3H]-cAMP accumulation in CHO tb6-m23 CRE-SPAP cells in
fering concentrations of mAb3. Concentration ratios were determined by dividing the
re mean ± s.e.m. from five individual experiments performed in triplicate. *p < 0.05
CGP 12177
Relative activity Log EC50 Concentration Ratio Emax % iso max
1 6.03 ± 0.21 – 9 ± 3
0.69 ± 0.11* 6.22 ± 0.29 0.81 ± 0.40 5 ± 3
0.19 ± 0.04* 6.12 ± 0.14 0.74 ± 0.36 5 ± 3
0.03 ± 0.01* 6.23 ± 0.04 0.83 ± 0.21 4 ± 2
Fig. 11. (a) Intracellular [3H]-cAMP accumulation in CHO tb6-m23 cells in response
to 1 lM isoprenaline for the first 60 min followed by 1 lM isoprenaline with 10 lM
CGP 20712A. (b) Intracellular [3H]-cAMP accumulation in CHO tb6-m23 cells in
response in response to 1 lM isoprenaline for the first 60 min followed by 1 lM
mAb3, 10 lM CGP 20712A, 1 lMmAb3 plus 10 lM CGP 20712A, or 1 lMmAb3 for
the first twelve minutes of the washout period, followed by 1 lM mAb3 in
combination with 10 lM CGP 20712A. Ligands were added after one hour
stimulation with 1 lM isoprenaline. Data are expressed as a percentage of
intracellular [3H]-cAMP stimulated by 1 lM isoprenaline for 60 min. Data points
are combined mean ± s.e.m. of from five separate experiments, each performed in
duplicate.
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cell lines expressing the tbtrunc or tb6-m23 variants of the turkey
b1-adrenoceptor we also investigated their signalling characteris-
tics. We found no evidence that mAb3 was able to stimulate cAMP
accumulation or downstream cAMP response element reporter
gene responses. This contrasts with previous data on mAb3 in tran-
siently transfected cells, where a small cAMP response was
reported [28]. This is most likely due to the very high expression
levels achieved with transient transfection. It has been docu-
mented previously that high receptor density can reveal partial
agonist behaviour of ligands previously characterised as antago-
nists [47,48]. MAb3 was, however, able to antagonise
isoprenaline-mediated activation of the two tb1-ARs. This was evi-
dent both at the level of cAMP accumulation and a downstream
reporter gene transcription. Schild analysis was consistent with a
non-competitive interaction between mAb3 and isoprenaline at
the tb6-m23 receptor. The reduction in the number of available
receptors in the presence of mAb3 (detected from binding studies
with both [3H]-CGP 12177 and the fluorescent analogue of CGP
12177) that can bind agonist almost certainly explains the effect
on signalling. Thus, the shift of the concentration-response curve
to isoprenaline to higher agonist concentrations produced bymAb3 can be explained by: (a) the reduced receptor number and
(b) the ability of the receptor reserve (due to signalling amplifica-
tion) to enable maximal functional responses to isoprenaline to be
achieved following a reduction in the receptor population. The data
obtained with mAb3 are consistent with an allosteric effect. How-
ever, it is also possible that the interaction of a bulky monoclonal
antibody with ECL2 might restrict access of agonists and antago-
nists to (or from) the orthosteric binding site deep within the
transmembrane regions of the b1-adrenoceptor [8,39], due to a
steric hindrance effect.
To investigate this possibility, the temporal profile of the
changes in intracellular cAMP levels was monitored following
sequential addition of isoprenaline and mAb3 or CGP 20712A.
Addition of CGP 20712A, after intracellular cAMP levels had
reached an equilibrium level following initial addition of isopre-
naline, led to a rapid fall in cellular cAMP levels. This was due to
the continuous binding and dissociation of isoprenaline that occurs
when equilibrium is reached, and the rapid occupancy of vacant
orthosteric binding sites that occurs when a high concentration
of the competitive antagonist CGP 20712A is subsequently added.
Addition of mAb3 led to a slower fall in cAMP levels that is consis-
tent with a negative allosteric interaction. In the absence of mAb3
or CGP 20712A, cAMP levels were maintained for 60 min. Simulta-
neous addition of mAb3 and CGP 20712A provided the same rapid
fall in cAMP to that obtained with CGP 20712A alone. These data
indicate that mAb3 did not reduce access of CGP 20712A to, or iso-
prenaline from, the orthosteric binding site. This was confirmed
when mAb3 was added first, to establish a slow fall in intracellular
cAMP, and then subsequent addition of CGP 20712A created a
rapid fall in cAMP levels.
It is very clear is that at the highest concentration of mAb3 used,
the allosteric effect of the antibody on [3H]-CGP 12177 binding is
confined to a subset/subpopulation of b1-ARs. The lack of effect
of this high concentration of mAb3 on the ligand affinity (isopre-
naline, propranolol, CGP 20712A) for the remaining [3H]-CGP
12177 specific binding sites is consistent with mAb3 only interfer-
ing with a specific conformation/sub-population of the b1-ARs. The
effect of mAb3 on b1-AR signalling suggests that the conformation/
sub-population of b1-AR targeted by the antibody is involved in
Gs-mediated agonist action. However, it remains to be established
whether this conformation (sensitive to inhibition by mAb3) repre-
sents the Gs-coupled b1-AR conformation.
In summary, the data obtained in the present study suggest that
mAb3 interacts with ELC2 to produce a pronounced negative allos-
teric effect on the binding of orthosteric ligands to a subset of tur-
key b1-adrenoceptors. It also elicited a negative allosteric effect on
functional Gs-mediated responses. The identity of the subset of
turkey b1-adrenoceptors influenced by mAb3 remains to be estab-
lished. It is well known that GPCRs can exist in a spectrum of con-
formations, ranging from resting R and active R⁄ states to
oligomeric complexes involving G protein, b-arrestin, scaffolding
proteins [49,50] and multiple GPCR molecules [51]. These confor-
mations have the potential to be selectively targeted by antibodies.
For example, single-domain camelid immunoglobulins (termed
nanobodies) have been utilised to recognise and stabilise active
(Nb80; [9,52,53]) and inactive (Nb60; [53]) conformations of the
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